Browse by author
Lookup NU author(s): JJ Wyatt, Dr Hazel McCallum
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2019 Elsevier B.V. Background and purpose: Magnetic Resonance (MR)-only prostate radiotherapy has recently been clinically implemented using commercial synthetic Computed Tomography (sCT) algorithms. However patients with hip prostheses have been excluded from all MR-only research to date and assumed to require dedicated sCT algorithms. This study aimed to investigate the dosimetric accuracy of applying a commercial sCT algorithm, based on an atlas of patients without hip prostheses, to patients with prostheses. Materials and methods: 18 patients with unilateral hip prostheses received MR and CT scans in the radiotherapy position. sCTs were generated from the MR using a commercial algorithm. The clinical Volumetric Modulated Arc Therapy (VMAT) plan, consisting of partial arcs which avoided the prosthesis, was recalculated using the sCT and the dose distribution compared. Results: The mean isocentre dose difference was ΔD = (−0.4 ± 0.2)% (mean ± standard error of the mean (sem), range – 1.9%, 1.1%) and the mean differences in Planning Target Volume, bladder and rectum mean doses were ≤0.3%. The 3D global gamma pass rate with dose difference 1% and distance to agreement 1 mm within the body was ΓBody 1/1 = (95.0 ± 0.5)% (sem) and within the 50% isodose volume, which excluded the prosthesis, was Γ50% 1/1 = (98.5 ± 0.4)% (sem). The pass rate within the PTV was ΓPTV 2/2 ≥ 99.7% for all patients, although for PTVs close (≤3.5 cm) to the prosthesis ΓPTV 1/1 < 85% for three patients. The sCT did not accurately represent the prosthesis with a mean difference in radiological isocentre depth near the prosthesis of ΔdOutside Rad = (15.8 ± 2.6) mm (sem). However inside the treatment plan arc the difference was ΔdInside Rad = (−1.8 ± 0.5) mm (sem). Conclusions: Using a commercial prostate sCT algorithm for patients with unilateral hip prostheses is dosimetrically accurate (<0.5%) as long as the routine prosthesis-avoidance treatment planning approach is used and the PTV is >3.5 cm from the prosthesis. This suggests MR-only prostate radiotherapy can be extended to patients with hip prostheses without requiring a specific sCT algorithm.
Author(s): Wyatt J, McCallum H
Publication type: Article
Publication status: Published
Journal: Radiotherapy and Oncology
Year: 2019
Volume: 133
Pages: 100-105
Print publication date: 01/04/2019
Online publication date: 22/01/2019
Acceptance date: 30/12/2018
ISSN (print): 0167-8140
ISSN (electronic): 1879-0887
Publisher: Elsevier Ireland Ltd
URL: https://doi.org/10.1016/j.radonc.2018.12.029
DOI: 10.1016/j.radonc.2018.12.029
Altmetrics provided by Altmetric
